UN 
Clinical trials for therapies targeting the Bundibugyo strain of the Ebola virus disease began last Thursday, July 2, in North Kivu province, Democratic Republic of Congo (DRC). The move comes as local hospitals report nearly 1,500 confirmed cases and over 450 deaths since the current outbreak was identified earlier this year, making it one of the most severe public health emergencies in Central Africa this summer.
The DRC Ministry of Public Health, in collaboration with the World Health Organization (WHO) and Médecins Sans Frontières, is coordinating the double-blind, randomized trial at two major treatment centers in Beni and Butembo. Dr. Aimée Kanku, head of infectious disease response in Beni, described Monday’s scene as “cautiously hopeful,” with international teams arriving amid persistent power outages and heavy seasonal rainfall.
The Bundibugyo strain, first detected in Uganda in 2007, has historically lacked a standardized, approved therapy. Existing vaccines and treatments for the Zaire Ebola strain have shown only limited effectiveness. This trial seeks to establish a globally recognized protocol for Bundibugyo, with interim results expected by the end of September 2026. Health officials stress that without a proven treatment, containment relies heavily on rapid isolation and contact tracing, both logistically challenging in the region’s rural, flood-affected villages.
The current response is under scrutiny from regional NGOs, which have raised concerns about supply chain delays and the transparency of data sharing. Meanwhile, DRC authorities are urging global donors to maintain support through the end of the rainy season, warning that the case fatality rate—holding at approximately 30%—could rise without improved access to care. The new clinical trial is seen as a critical step towards SDG 3 (Good Health & Well-being), but experts warn that delivery, not just announcement, will determine real progress.
Over the next several weeks, trial organizers plan to enroll up to 300 patients, with the hope that findings will inform wider deployment across the Great Lakes region by early 2027. For now, families in Beni and surrounding areas continue to navigate nightly curfews and limited transportation as the health emergency enters its fifth month.
Frequently Asked Questions
When did the DRC begin clinical trials for the Bundibugyo Ebola strain?
Clinical trials for therapies targeting the Bundibugyo Ebola strain began on July 2 in North Kivu province, DRC.
How many cases and deaths have been reported in the current Bundibugyo Ebola outbreak in the DRC?
Nearly 1,500 confirmed cases and over 450 deaths have been reported since the outbreak began earlier this year.
Who is coordinating the Bundibugyo Ebola clinical trial in the DRC?
The trial is coordinated by the DRC Ministry of Public Health, the World Health Organization (WHO), and Médecins Sans Frontières.
What is the expected timeline for interim results from the Bundibugyo Ebola clinical trial?
Interim results from the double-blind, randomized trial are expected by September 2026.
What is the case fatality rate for the Bundibugyo Ebola outbreak in the DRC?
The case fatality rate is approximately 30%.
